

Electronic Acknowledgement Receipt

EFS ID:	1448770
Application Number:	10078927
International Application Number:	
Confirmation Number:	6357
Title of Invention:	Cyclin dependent kinase 5 phosphorylation of disabled 1 protein
First Named Inventor/Applicant Name:	Thomas Curran
Customer Number:	28258
Filer:	Shawn Annette Hawkins/Regina McKinney
Filer Authorized By:	Shawn Annette Hawkins
Attorney Docket Number:	SJ-01-0032
Receipt Date:	18-JAN-2007
Filing Date:	19-FEB-2002
Time Stamp:	17:01:47
Application Type:	Utility

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1		011807AppealBriefandCover Letter.pdf	25757150	yes	50

	Multipart Description/PDF files in .zip description		
	Document Description	Start	End
	Miscellaneous Incoming Letter	1	1
	Appeal Brief Filed	2	50
Warnings:			
Information:			
Total Files Size (in bytes):		25757150	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>			